39,837 Shares in Humana Inc. (NYSE:HUM) Acquired by Resona Asset Management Co. Ltd.

Resona Asset Management Co. Ltd. purchased a new stake in Humana Inc. (NYSE:HUM) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 39,837 shares of the insurance provider’s stock, valued at approximately $10,117,000.

Several other institutional investors and hedge funds also recently made changes to their positions in the stock. FPC Investment Advisory Inc. bought a new stake in Humana in the 4th quarter valued at $27,000. Centricity Wealth Management LLC acquired a new stake in shares of Humana in the 4th quarter valued at about $30,000. LFA Lugano Financial Advisors SA lifted its holdings in shares of Humana by 56.3% in the fourth quarter. LFA Lugano Financial Advisors SA now owns 125 shares of the insurance provider’s stock valued at $32,000 after purchasing an additional 45 shares in the last quarter. OFI Invest Asset Management acquired a new position in shares of Humana during the fourth quarter worth about $33,000. Finally, Atwood & Palmer Inc. grew its holdings in shares of Humana by 64.5% during the fourth quarter. Atwood & Palmer Inc. now owns 153 shares of the insurance provider’s stock worth $39,000 after buying an additional 60 shares in the last quarter. Institutional investors and hedge funds own 92.38% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on the company. Cantor Fitzgerald reaffirmed a “neutral” rating and set a $290.00 price target on shares of Humana in a research report on Wednesday, February 12th. Royal Bank of Canada restated an “outperform” rating and set a $283.00 target price on shares of Humana in a report on Wednesday, February 12th. Truist Financial lifted their price target on shares of Humana from $260.00 to $290.00 and gave the company a “hold” rating in a research note on Monday, January 6th. StockNews.com downgraded shares of Humana from a “buy” rating to a “hold” rating in a research note on Tuesday, March 18th. Finally, Barclays lifted their target price on Humana from $255.00 to $270.00 and gave the company an “equal weight” rating in a research report on Thursday, February 13th. Eighteen research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $280.17.

Humana Stock Down 4.6 %

Humana stock opened at $253.37 on Monday. The company’s 50-day moving average price is $267.58 and its two-hundred day moving average price is $271.55. The stock has a market cap of $30.58 billion, a P/E ratio of 25.46, a P/E/G ratio of 2.05 and a beta of 0.62. Humana Inc. has a twelve month low of $213.31 and a twelve month high of $406.46. The company has a quick ratio of 1.76, a current ratio of 1.76 and a debt-to-equity ratio of 0.68.

Humana (NYSE:HUM) last posted its earnings results on Tuesday, February 11th. The insurance provider reported ($2.16) earnings per share for the quarter, topping analysts’ consensus estimates of ($2.26) by $0.10. Humana had a return on equity of 11.70% and a net margin of 1.02%. As a group, analysts expect that Humana Inc. will post 16.47 EPS for the current year.

Humana Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, April 25th. Investors of record on Friday, March 28th will be paid a $0.885 dividend. This represents a $3.54 annualized dividend and a dividend yield of 1.40%. The ex-dividend date is Friday, March 28th. Humana’s dividend payout ratio (DPR) is currently 35.58%.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.